Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Arbutus Biopharma Corp
ABUSCurrent price
3.73 USD
-0.19 USD (-4.85%)
Last closed
3.92 USD
Company
www.arbutusbio.com
ISIN
CA03879J1003
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
747 576 704 USD
Yield for 12 month
+99.47 %
1Y
3Y
5Y
10Y
15Y
ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Address: 701 Veterans Circle, Warminster, PA, United States, 18974
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5 USDP/E ratio
–Dividend Yield
–Current Year
+18 141 000 USD
Last Year
+39 019 000 USD
Current Quarter
+1 726 000 USD
Last Quarter
+1 532 000 USD
Current Year
+16 737 000 USD
Last Year
+37 592 000 USD
Current Quarter
+1 370 000 USD
Last Quarter
+1 177 000 USD
Key Figures ABUS
1 year
3 years
5 years
10 years
EBITDA
-80 989 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-30.59 %
PEG Ratio
–
Return On Equity TTM
-59.96 %
Wall Street Target Price
5 USD
Revenue TTM
10 061 000 USD
Book Value
0.65 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-62.9 %
Dividend Yield
–
Gross Profit TTM
-45 389 000 USD
Earnings per share
-0.45 USD
Diluted Eps TTM
-0.45 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ABUS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ABUS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:5
Payout Ratio
–
Last Split Date
04.11.2010
Dividend Date
–
Stock Valuation ABUS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
60.3506
Price Sales TTM
74.3044
Enterprise Value EBITDA
-5.636
Price Book MRQ
6.105
Financials ABUS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ABUS
For 52 weeks
1.7 USD
4.73 USD
50 Day MA
4.04 USD
Shares Short Prior Month
7 358 461
200 Day MA
3.29 USD
Short Ratio
6.52
Shares Short
7 791 428
Short Percent
5.24 %
BeatStart